BCP also attenuated neuronal necrosis, receptor-interaction protein kinase-1 (RIPK1), receptor-interaction protein kinase-3 (RIPK3) expression, and mixed lineage kinase domain-like protein (MLKL) phosphorylation in cerebral ischemia by inhibiting high-mobility group box 1 (HMGB1)-toll-like receptor 4 (TLR4) signaling pathways and proinflammatory cytokines. The gene discussed is TLR4; the disease is brain ischemia.